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Abstract
Rationale Therapeutic agents for memory enhancement in
psychiatric disorders, such as schizophrenia, are urgently
needed.
Objective The aim of this study is to characterize the preclin-
ical profile of ITI-214, a potent inhibitor of phosphodiesterase
1 (PDE1).
Methods ITI-214 was assayed for inhibition of PDE1 versus
other PDE enzyme families using recombinant human PDE
enzymes and for off-target binding to 70 substrates (General
SEP II diversity panel; Caliper Life Sciences). Effects of ITI-
214 (0.1–10 mg/kg, po) on memory performance were
assayed in rats using the novel object recognition (NOR) par-
adigm, with drug given at specified time points prior to or
following exposure to objects in an open field. ITI-214 was
evaluated for potential drug-drug interaction with risperidone
in rats using conditioned avoidance response (CAR) and phar-
macokinetic assessments.
Results ITI-214 inhibited PDE1A (Ki = 33 pmol) with >1000-
fold selectivity for the nearest other PDE family (PDE4D) and
displayed minimal off-target binding interactions in a 70-
substrate selectivity profile. By using specific timing of oral
ITI-214 administration, it was demonstrated in the NOR that
ITI-214 is able to enhance acquisition, consolidation, and re-
trieval memory processes. All memory effects were in the
absence of effects on exploratory behavior. ITI-214 did not
disrupt the risperidone pharmacokinetic profile or effects in
CAR.
Conclusions ITI-214 improved the memory processes of ac-
quisition, consolidation, and retrieval across a broad dose
range (0.1–10 mg/kg, po) without disrupting the
antipsychotic-like activity of a clinical antipsychotic medica-
tion, specifically risperidone. Clinical development of ITI-214
is currently in progress.
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Introduction
The cyclic nucleotide second messengers, cAMP and cGMP,
have been well-characterized as intracellular signaling mole-
cules in the brain where they have been implicated in the
control of diverse processes including motor movement,
learning, memory, and emotion. Cyclic nucleotide levels are
determined by the balance between the adenylyl and guanylyl
cyclases that catalyze their formation and the phosphodiester-
ase (PDE) enzymes that catalyze their hydrolysis and inacti-
vation. The PDE superfamily is comprised of 11 families of
PDE enzymes that are encoded by at least 21 distinct genes
and classified based on substrate specificities (e.g.,
cAMP/cGMP) and regulatory factors (Conti and Beavo
2007; Francis et al. 2011). These enzymes display unique
tissue distributions that differ among individual PDE families
* Gretchen L. Snyder
gsnyder@intracellulartherapies.com
1 Intra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New
York, NY 10016, USA
2 Department of Psychiatry and Neuropsychology, School for Mental
Health and Neuroscience, Maastricht University, P.O. Box 616,
NL-6200 Maastricht, MD, The Netherlands
3 School of Natural Sciences, Linnaeus University, Kalmar, Sweden




and structurally-related isoforms within the same enzyme
family (Bender and Beavo 2006; Lakics et al. 2010).
Several PDE enzymes are expressed in abundance in the
central nervous system (CNS) (Lakics et al. 2010). Certain of
these enzymes are believed to modulate memory processes
through regulation of cyclic nucleotide-dependent signaling
pathways (Rutten et al. 2007; Reneerkens et al. 2009). Both
cAMP and cGMP pathways, modulated by individual PDE
families, have been shown to contribute to specific phases of
memory (Izquierdo et al. 2002; Bollen et al. 2014; Rutten et al.
2007). Members of the PDE1 family are dual-substrate en-
zymes that hydrolyze and inactivate both cGMP and cAMP.
Furthermore, within the PDE superfamily of enzymes, PDE1
is uniquely regulated by calcium/calmodulin-dependent sig-
naling pathways (Bentley et al. 1992). Evidence suggests that
PDE1 activity may be governed by phasic variations in
calcium/calmodulin availability secondary to neuronal activi-
ty (Polli and Kincaid 1992; Polli and Kincaid 1994; Siuciak et
al. 2007). There are three identified PDE1 isoforms (1A, 1B,
and 1C) which are abundant in brain regions that subserve
memory and learning, including frontal cortex, hippocampus,
and striatum (Lakics et al. 2010). For example, the PDE1B
isoform is highly enriched in neurons of the striatum and fron-
tal cortex possessing cAMP signaling pathways controlled by
dopamine D1-type receptors (Polli and Kincaid 1994; Lakics
et al. 2010). Activation of dopamine D1 receptors on cortical
neurons can enhance memory function (Castner et al. 2000)
and, further, may be a plausible therapeutic approach toward
overcoming cognitive impairment associatedwith schizophre-
nia and other CNS disorders (Castner et al. 2000; Goldman-
Rakic et al. 2004).
Cognitive impairment is a core feature of psychiatric dis-
orders such as schizophrenia that is largely unresponsive to
antipsychotic medications (Tamminga et al. 1998; Hoff et al.
1999). Effective treatments for cognitive impairments in
schizophrenia are needed as they can have a beneficial effect
on functional outcome (Kahn and Keefe 2013). Short-term
memory, which is relevant to memory acquisition processes
(Akkerman et al. 2016), is in the domain of cognitive func-
tions known to be impaired in schizophrenia (Targum and
Keefe 2008). The novel object recognition (NOR) paradigm
is useful for studying memory performance in rodents. This
paradigm focuses, in particular, on memory processes such as
acquisition, consolidation, and retrieval (Ennaceur and
Delacour 1988; van Goethem et al. 2012). The latter two pro-
cesses are required for long-term memory, which might be
relevant for other psychiatric disorders, including
Alzheimer’s disease. NOR is a valuable tool for identifying
therapies preclinically which could enhance memory, al-
though the clinical utility of such therapies must ultimately
be evaluated in patients with schizophrenia, as some com-
pounds (e.g., aripiprazole) have been falsely identified as ben-
eficial for cognitive impairment, based on NOR results
(Karamihalev et al. 2014; Nagai et al. 2009; Rajagopal et al.
2014). Of the various behavioral paradigms available for
screening for potential cognitive improvement, NOR was se-
lected given that effects of other PDE inhibitors have been
well-characterized in this assay. In the context of cGMP-
mediated effects versus cAMP-mediated effects on memory
behavior by other selective PDE inhibitors, NOR could allow
for characterization and interpretation of PDE1 inhibitors with
dual substrate effects (Rutten et al. 2006; Rutten et al. 2007;
Bollen et al. 2014).
An important requirement in developing therapies for treat-
ment of cognitive impairment in patients with schizophrenia is
the maintenance of efficacy of antipsychotic medications that
are the standard of care for major psychotic symptoms of the
disease. The conditioned avoidance response (CAR) assay is a
well-characterized and widely-used rodent assay for screening
compounds with antipsychotic-like activity (for review, see
Wadenberg and Hicks 1999). The assay has predictive value
for assessing antipsychotic-like activity since all clinically ef-
fective antipsychotic medications selectively suppress the
CAR response (Arnt 1982;Wadenberg 2010). Used in concert
with the NOR assay, CAR can be used to evaluate the poten-
tial of promising cognition enhancing therapies to improve
memory performance without compromising the efficacy of
a concurrent antipsychotic medication. Of note, no animal
model of cognition, however, has translated into cognitive
benefit for schizophrenia, to date.
Recently, we have discovered a portfolio of potent, selec-
tive, and brain permeant inhibitors of PDE1 (Li et al. 2016),
enabling for the first time an examination of the role of PDE1
in memory function. One of these novel PDE1 inhibitors, ITI-
214, is an investigational new drug that has recently been
evaluated and found to be safe and well-tolerated in human
clinical trials in healthy volunteers and patients with schizo-
phrenia. Here, we present data from the preclinical character-
ization of ITI-214 in rats, indicating that the compound pro-
motes improved memory performance in rats.
Materials and methods
Materials
ITI-214 (MW = 508) is (6aR,9aS)-2-(4-(6-fluoropyridin-2-
yl)benzyl)-5-methyl-3-(phenylamino)-5,6a,7,8,9,9a-
hexahydrocyclopenta-[4,5]imidazo[1,2-a]pyrazolo[4,3-e-
]pyrimidin-4-(2H)-one phosphate salt that was first synthe-
sized by the medicinal chemistry department at Intra-
Cellular Therapies Inc. (ITI). Risperidone and paliperidone
(as reference compounds) were obtained from R&D Systems
(Minneapolis, MN). Immobilized metal affinity fluorescence
polarization (IMAP) reagents, including reaction buffer, bind-
ing buffer, Fl-cAMP, and IMAP beads, were from Molecular
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Devices (Sunnyvale, CA). FuGene6 transfection reagent and
protease inhibitor cocktail tablets (Complete™, Mini, EDTA-
free protease inhibitor cocktail tablets; Cat. No. 11 836 170
001) were fromRoche Applied Science (Indianapolis, IN). All
other chemicals were from Sigma-Aldrich (St. Louis, MO).
Measurements of phosphodiesterase activity in vitro
Phosphodiesterases 1A, 1B, 1C, 2A, 3B, 4A, 5A, 7B, 8A, 9A,
10A, and 11Awere generated from full-length human or bo-
vine recombinant clones (designated below as r-xPDE). PDE6
was isolated from bovine retina.
PDE enzyme preparations The following PDE enzymes
were used: r-hPDE1A (HEK) (Accession No. NM_005019,
Homo sapiens phosphodiesterase 1A, calmodulin-dependent,
transcript variant 1); r-hPDE1B (HEK) (Accession No.
NM_000924, Homo sapiens phosphodiesterase 1B, calmod-
ulin-dependent, transcript variant 1); r-hPDE1C (HEK)
(Accession No. NM_005020.1, Homo sapiens phosphodies-
terase 1C, calmodulin-dependent); r-hPDE2A (Accession No.
NM_002599, Homo sapiens phosphodiesterase 2A, cGMP-
stimulated, transcript variant 1); r-hPDE3B (Accession No.
NM_000922, Homo sapiens phosphodiesterase 3B)
expressed in Spodoptera frugiperda insect cells (Sf9) using a
baculovirus expression system, was from BPS Bioscience
(San Diego CA, Cat. No. 60031); r-hPDE4A1A (Accession
No. U97584, Homo sapiens phosphodiesterase 4A, transcript
variant 1) expressed in Sf9 cells using a baculovirus expres-
sion system (BPS Bioscience, Cat. No. 60040); r-bPDE5A
(Accession No. NM_174417, Bos taurus phosphodiesterase
5A) expressed in Sf9 cells; bPDE6 (from bovine retina rod)
isolated from bovine retinas (Arvys Protein, Stamford, CT); r-
hPDE7B (Accession No. NM_018945, Homo sapiens phos-
phodiesterase 7B) expressed via transient transfection of
HEK293 cells; r-hPDE8A (Accession No. NM_002605,
Homo sapiens phosphodiesterase 8A, transcript variant 1)
expressed in Sf9 cells using a baculovirus expression system
(BPS Bioscience, Cat. No. 60080); r-hPDE9A (Accession No.
NM_002606,Homo sapiens phosphodiesterase 9A, transcript
variant 1 was expressed via transient transfection of HEK293
cells; r-hPDE10A (Accession No. NM_006661, Homo
sapiens phosphodiesterase 10A, transcript variant 2); and r-
hPDE11A4 Accession No. BAB62712, Homo sapiens phos-
phodiesterase 11A, transcript variant 4) expressed in Sf9 cells
using a baculovirus expression system was purchased from
(BPS Bioscience, Cat. No. 60110).
Transient transfection Transient transfection of HEK293
cells with recombinant protein expression vectors was per-
formed using FuGENE 6 Transfection Reagent (Cat. No. 11
988 387 001, Roche Applied Science) according to the man-
ufacturer’s recommendations. Mammalian expression cloning
vectors with recombinant cDNA copies of each PDE gene
were purchased from OriGene. Protein was expressed via
transient transfection in HEK293 cells. Other PDE enzymes
were expressed in Sf9 insect cells using the Bac-to-Bac
baculoviral expression system (Invitrogen) according to the
manufacturer’s instructions. After 48 h, cells were processed
to obtain the soluble cytosolic fraction for assay.
PDE assays PDE assays were performed in a reaction medi-
um containing 10 mM Tris-HCl (pH 7.2), 10 mM MgCl2,
0.1 % BSA, and 45 nM Fl-cGMP or Fl-cAMP, respectively.
IMAP assays were carried out for 15 min at room temperature
and terminated by addition of binding reagent (Molecular
Devices). Reaction mixture for assay of PDE1 activity also
contained 30 μM CaCl2 and 10 U/ml calmodulin. The reac-
tion mixture for assay of PDE2 contained 2 μM cGMP.
Fluorescent-labeled cGMP (Fl-cGMP) was used as the sub-
strate in the assays for PDE1, PDE5A, PDE6, and PDE9A,
while fluorescent-labeled cAMP (Fl-cAMP) was used as the
substrate for PDE2A, PDE3B, PDE4A, PDE7B, PDE8A,
PDE10A, and PDE11A. Inhibitory concentration (IC50)
values were calculated using nonlinear regression software,
fitting a four-parameter one-site dose-response model
(XLFit; IDBS, Cambridge, MA) and converted to Ki values
using the Cheng-Prusoff equation (Cheng and Prusoff 1973).
Off-target binding of ITI-214
The propensity of ITI-214 to bind biological target proteins
unrelated to PDE family enzymes was evaluated by interro-
gating a panel of 70 key receptor, enzyme, and ion channel
proteins comprising a diversity panel screen (General Side
Effect Profile SEPII) performed by Caliper Life Sciences
(now PerkinElmer). ITI-214 binding to each substrate was
expressed as a mean percent of the reference control (n = 2
measurements) collected at a single, high (10 μM) concentra-
tion of drug.
Treatment of animals for in vivo experiments
Rats Male Sprague-Dawley rats (150–200 g), obtained from
Charles River Laboratories (Wilmington, MA), were used for
pharmacokinetic studies to evaluate possible drug-drug inter-
actions with antipsychotic agents as performed at ITI using
established protocols with this strain of rat. Wistar rats were
used for all behavior studies, using established protocols in
both the Prickaerts and Wadenberg labs. Male Wistar rats
(280–350 g) were obtained from Charles River Laboratories
(The Netherlands) for novel object recognition studies per-
formed at The University of Maastricht (Maastricht,
The Netherlands). Male Wistar rats (300–500 g) were used
for tests of conditioned avoidance response in studies per-
formed at Linnaeus University (Kalmar, Sweden). In all cases,
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animals were maintained in standard laboratory conditions
under a 12-h light/dark cycle, except Maastricht with a re-
versed cycle, with food and water available ad libitum with
a minimum of 1 week acclimation prior to experimentation.
All animals were cared for in accordance with the Institute of
Laboratory Animal Resources (1996), and all procedures were
performed with the approval of the Institutional Animal Care
and Use Committees at the respective institutions and contract
research organizations.
Compound formulation for animal dosing Unless other-
wise indicated, ITI-214 was dissolved in a solution of
20 nM citrate buffer (pH 3.5) in 0.5 % (w/v) carboxymethyl-
cellulose (CMC, 400–800 cP, #C4888; Sigma-Aldrich
Chemical Co., Inc.) in water. The drug was administered,
per os (po), by gavage to rats in a volume of 2 ml/kg body
weight. Oral dosing solutions were prepared fresh daily.
Risperidone was prepared for systemic dosing in the CAR
studies by solubilization in a small volume of glacial acetic
acid, which was further diluted with addition of a 5.5 % glu-
cose solution (pH ~4.0). The pH of the dosing solution was
adjusted to ~pH 5.5 by dropwise addition of 0.1 N NaOH in
saline and volume adjusted by addition of saline in preparation
for intraperitoneal (ip) dosing. For oral dosing, risperidone
was suspended in a solution of 0.5 % CMC in water using
bath sonication, and a suspension of drug was administered to
rats via gavage (2 ml/kg body weight). Control treatments
were always the vehicle solutions of the corresponding drugs.
Measurement of memory performance using the novel
object recognition paradigm
Object recognition memory The object recognition test was
performed as described elsewhere (Ennaceur and Delacour
1988; Akkerman et al. 2014). The apparatus consisted of a
circular arena, 83 cm in diameter. Half of the 40-cm-high wall
was made of gray polyvinyl chloride, the other half of trans-
parent polyvinyl chloride. The light intensity was equal in the
different parts of the apparatus, as fluorescent red tubes pro-
vided a constant illumination of about 20 lx on the floor of the
apparatus. Two objects were placed in a symmetrical position
at about 10 cm from the gray wall. Four different sets of
objects were used. The different objects were (1) a cone
consisting of a gray polyvinyl chloride base (maximal diame-
ter 18 cm) with a collar on top made of brass (total height
16 cm), (2) a standard 1 L transparent glass bottle (diameter
10 cm, height 22 cm) filled with water, (3) a large metal cube
(10.0 × 5.0 × 7.5 cm) with two holes (diameter 1.9 cm), and
(4) a large aluminum cube with a tapering top (13.0 × 8.0 ×
8.0 cm). The objects used in this study were carefully se-
lected to be Bnovelty neutral,^ that is to say the rats have
no innate preference for one over the other. In all cases,
objects were of sufficient size and weight that rats could
not move the objects.
A testing session consisted of two trials. The duration of
each trial was 3 min. During the first trial (T1), the apparatus
contained two identical objects (samples). Rats were placed in
the apparatus facing the wall at the middle of the front
(transparent) segment. After the first exploration period, the
rat was put back in its home cage. Subsequently, after a 24-h
delay interval, the rat was put in the apparatus for the second
trial (T2). The times spent in exploring each object during T1
and T2 were recorded manually using a personal computer.
Exploration was defined as follows: directing the nose to
the object at a distance of no more than 2 cm and/or touching
the object with the nose. Sitting on the object was not consid-
ered as exploratory behavior. In order to avoid the presence of
olfactory cues, the objects were always thoroughly cleaned
with a 70 % ethanol solution before each trial. All combina-
tions and locations of objects were used in a balanced manner
to reduce potential biases due to preferences for particular
locations or objects.
Procedure During the first 2 weeks after animal arrival, the
animals were handled daily. They were then adapted to the
procedure over the period of 2 days by allowing them to ex-
plore the apparatus (without any objects) for 3 min twice each
day. The rats were considered to be adapted to the testing
protocol when they showed a stable discrimination perfor-
mance, i.e., a good discrimination after a 1-h interval and no
discrimination after a 24-h interval (data not shown; for
protocol, see Akkerman et al. 2012a). After this, the rats were
assigned to treatment conditions in a balanced manner, there-
by insuring an equal distribution of object combinations
among the treatment conditions. In a first batch of 20 rats,
drug was injected (0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, and
3 mg/kg, given at 2 ml/kg po) either 2 h prior to T1 to test
the dose response of ITI-214 for effects on memory acquisi-
tion or 2 h prior to T2 to test memory retrieval. Subsequent
experiments with an additional cohort of 20 rats evaluated the
effect of ITI-214 on early and late consolidation ofmemory by
administering the drug at 4 min or 3 h after T1 (as described in
Bollen et al. 2015). In all experiments, a 24-h inter-trial inter-
val was used. In all cases, the experimenter was unaware of
the treatment conditions that were being tested.
Statistical analysis The basic measure recorded was the time
spent by each rat exploring an object during T1 and T2. The time
spent in exploring the two identical samples was represented by
Ba1^ and Ba2.^ The time spent in T2 in exploring the sample and
new object was represented by Ba^ and Bb,^ respectively. The
following variables were calculated: e1 = a1 + a2, e2 = a + b,
and d2 = (b − a) / e2. The e1 and e2 are measures of the total
exploration time of both objects during T1 and T2, respectively.
Differences in exploration times between treatment conditions
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were analyzed using a t test or one-way ANOVA. The d2 (dis-
crimination index) is a relative measure of discrimination
corrected for exploration activity (e2). Thus, the formula corrects
for any differences between conditions in T2 exploration. One-
sample t statistics were performed in order to assess per treat-
ment condition whether d2 differed from zero (i.e., chance per-
formance). However, comparison of the value of d2 with the
value zero may not be the most suitable way for analyzing
recognition (increased chance of making a type I error)
(Akkerman et al. 2012b). Effects were, therefore, also assessed
by a t test or one-way ANOVA. In case the ANOVA showed a
significant difference between treatments, conditions were ana-
lyzed in more detail using post hoc Bonferroni t tests. A d2 of a
treatment condition being different from zero as well as from its
vehicle/control condition is considered to reflect a Bfull^ effect,
while only being different from zero is referred to as an
Bintermediate^ effect (Akkerman et al. 2012b).
Pharmacokinetic study of drug-drug interactions
between ITI-214, risperidone, and its primary metabolite,
paliperidone in rats
In-life procedures Adult, male Sprague-Dawley rats (200–
250 g in body weight; n = 3 rats/treatment condition) were
administered vehicle (0.5 % CMC in water) or ITI-214
(3 mg/kg in vehicle) by gavage (po). All rats received a dose
of risperidone (2mg/kg, po) prepared as an even suspension in
0.5 % CMC. One hour later, the rats were killed and blood and
brain tissue were collected. Brain tissue was transferred to
Eppendorf tubes, then frozen at −80 °C until analysis.
Blood, collected into tubes containing sodium citrate, was
centrifuged (2000g × 15 min at 4 °C). Plasma was decanted
into clean Eppendorf tubes and frozen at −80 °C until analysis.
Levels of ITI-214, risperidone, and the major metabolite of
risperidone, paliperidone, were quantitated in brain homoge-
nates and in plasma, using standard reverse-phase high-pres-
sure liquid chromatography with mass-spectrometric detec-
tion (HPLC/MS). Levels of each compound were expressed
as ng/ml ± SD.
LC/MS analysis of drug in plasma and brain Standard
methods of tissue extraction were used. Whole brain was soni-
catedwith20mMTris-HCl, 135mMNaCl, pH7.4buffer, giving
a 200 mg/ml (w/v) homogenate. Brain homogenate or plasma
was then extracted with two volumes of acetonitrile and clarified
by centrifugation at 12,000g for 20 min. Extracts were separated
byHPLCusing aWatersAlliance 2695 separationmodulewith a
Sunfire™ C18 column (3.5 μm, 2.1 × 50 mm) and a gradient of
methanol over30min in amobilephaseof0.1%formic acidwith
the separationmonitored by LC-MS. Compound standardization
was performed bymethods analogous to those previously report-
ed (Zhao et al. 2005; Appels et al. 2005). Brain and plasma
concentration and ratio (brain/plasma) were calculated for
each compound.
Measurement of conditioned avoidance responding in rats
CAR apparatus and protocol The behavioral procedures
were conducted as described previously (Wadenberg et al
2007; Wiker et al. 2008). Briefly, adult male Wistar rats (n =
8) were trained and tested in a manually operated conventional
shuttle box (530 × 250 × 225 mm; Kungsbacka Mät-och
Reglerteknik, Kungsbacka, Sweden), divided into two equal
compartments by a partition with an opening (75 × 75 mm).
Upon presentation of an 80-dB white noise (White Noise
Generator, USA), used as conditioned stimulus (CS), the rat
had 10 s to avoid the unconditioned stimulus (UCS), an inter-
mittent electric shock (~0.2 mA; with an inter-shock interval
of 2.5 s, shock duration 0.5 s) in the grid floor, by moving into
the opposite compartment. The shock was terminated within
50 s if rats failed to respond. Avoidance behavior, escape
behavior, escape failures, and inter-trial crosses were record-
ed, as described here: (1) avoidance (response to CS within
10 s); (2) escape (response to CS + UCS); and (3) escape
failure (if the rat was unable to respond to the shock by mov-
ing into the opposite compartment within 50 s, the trial was
terminated). The inter-trial interval (end of trial to start of new
trial) varied randomly between 20 and 40 s. Rats were trained
for five consecutive days and adapted to the shuttle box 5 min
before each training session. Training sessions consisted of
about 20 trials, randomly distributed over 15 min. Only rats
that performed at least 90 % avoidance on the last day of
training were included in the experiments. All subsequent test
sessions were preceded by a pre-test to verify continued per-
formance in the paradigm. Pre-tests and test sessions consisted
of approximately ten trials, each randomly distributed over a
7.5-min period. The same animals were tested repeatedly serv-
ing as their own controls (i.e., all rats received all treatments)
in a change-over design (Li 1964). Experimental days were
always separated by at least two non-experimental days.
Experimental tests were separated by at least 2 days to insure
drug washout.
Statistical analysis Results from the conditioned avoidance
responding (CAR) protocol were analyzed using non-
parametric procedures. Statistical evaluation was performed
by means of the Friedman two-way ANOVA by ranks follow-
ed by post hoc comparisons using the Wilcoxon matched-
pairs signed-ranks test (Siegel and Castellan 1988).
Results
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yl)benzyl)-5-methyl-3-(phenylamino)-5,6a,7,8,9,9a-
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hexahydrocyclopenta-[4,5]imidazo[1,2-a]pyrazolo[4,3-e-
]pyrimidin-4-(2H)-one phosphate salt (Li et al. 2016). The
compound is a novel small-molecule investigational drug
Fig. 1 Synergistic effects of ITI-214 on memory performance in the
novel object recognition paradigm in rats. Memory performance was
measured inmaleWistar rats using a 24-h interval. Rats were dosed orally
with ITI-214 at the indicated doses and times relative to the T1 and T2 test
periods to evaluate drug effect onmemory acquisition (a) and retrieval (b)
and to determine the optimal dose(s) of the compound for enhancement of
memory performance. In c, a suboptimal dose of ITI-214 for memory
acquisition (0.3mg/kg, panel a) was administered to rats 2 h prior to T1 in
combination with a suboptimal dose of ITI-214 for memory retrieval
(0.1 mg/kg, panel b), which was administered 2 h prior to T2. Memory
performance was then measured in T2. For all experiments, the discrim-
ination index (d2) was calculated as a measure of time spent during T2 in
contact with the novel object, compared with the familiar object.
Discrimination index (d2) is expressed as mean ± SEM for n = 20 rats
per experimental condition. The d2 measured after drug treatment was
significantly different from zero (#p < 0.05; ##p < 0.01; ###p < 0.001,
one-sample t test) and from vehicle condition [***p < 0.001, Bonferroni
post hoc tests (b) or t test (c)]
Table 1 Inhibitory constant (Ki) values for ITI-214 measured against a
panel of phosphodiesterase isoforms. Values were determined as de-
scribed in BMaterials and methods^ section using bovine or human re-
combinant enzymes, as indicated. Since for all PDE assays, substrate
concentration was below Km for the enzyme data are reported as Ki
values. Ki values for ITI-214 against each PDE isoform were then
expressed as a ratio over the Ki of the compound for human recombinant
PDE1A enzyme








r-bovine PDE5A 0.63 19,090






hPDE1A human recombinant PDE1A, hPDE1B human recombinant
PDE1B, hPDE1C human recombinant PDE1C, hPDE2A human recom-
binant PDE2A, hPDE3B human recombinant PDE3B, hPDE4A human
recombinant PDE4A, r-bovine PDE5A recombinant bovine PDE5A,
hPDE7B human recombinant PDE7B, hPDE8A human recombinant
PDE8A, hPDE9A human recombinant PDE9A, hPDE10a human recom-
binant PDE10A, hPDE11A human recombinant 11A
Table 2 Off-target binding of ITI-214 to a 70-substrate side effect
profile diversity panel (General SEP II) was conducted by Caliper Life
Sciences (PerkinElmer) using a single drug concentration of 10 μM ITI-
214, a concentration that is ~300,000-fold in excess of the Ki for PDE1
enzyme. A significant binding interaction in the assay was defined as
>50 % binding to the target. The ten highest off-target binding interac-
tions are shown in the table
Specificity profile for ITI-214—20 highest off-target interactions
Target % Binding
Na+ channel (site 2), sodium channel 88.44
Ca2+ channel (L, DHP site) 73.28
NK3 (h), neurokinin 64.65
DA transporter (h), dopamine 58.70
Alpha 1 (non-selective), adrenergic 40.90
Potassium channel I[Kr], (hERG) 35.09
Alpha 2 (non-selective), adrenergic 34.94
H3 (h), histamine 32.54
NK1 (h), neurokinin 30.93
B2 (H), bradykinin 30.79
h human, DHP dihydropyridine, hERG human ether-à-go-go-related
gene
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currently under human clinical evaluation as a medication for
the treatment of psychiatric and neurodegenerative disorders.
PDE potency and selectivity of ITI-214
ITI-214 was found to potently inhibit the activity of full-length
recombinant r-hPDE1A (Ki = 34 pM), r-hPDE1B (Ki =
380 pM), and r-hPDE1C (Ki = 37 pM) enzymes transiently
expressed in HEK cells. The compound expressed >1000-
fold greater activity toward PDE1 isoforms compared with
the next nearest PDE family enzyme, PDE4D (Ki = 33 nM)
and 10,000–300,000-fold selectivity toward all other PDE en-
zyme families (Table 1).
Off-target selectivity of ITI-214
ITI-214was assayed for potential off-target interactions against a
standard panel of key proteins, including neurotransmitter recep-
tors, ion channels, ion pumps, synthetic enzymes, and transport-
er proteins. This 70-target diversity panel [Side Effect Profile
(SEP) II, Caliper Life Sciences], performed at a drug concentra-
tion of 10 μM, or roughly 300,000-fold in excess of the Ki of
ITI-214 for inhibition of the PDE1A isoform, identified only 4
substrates showing >50 % binding to ITI-214, including Na+
channel (site 2), Ca2+ channel (L, DHP site), NK3, neurokinin
receptor, and the dopamine transporter (Table 2).
The effect of ITI-214 on NOR in rats
Based on pharmacokinetic studies of ITI-214 in which a brain
Tmax at ~1.5 hwas observed, we selected a 2-h drug pretreatment
time for studies on memory processes and employed the NOR
test with a 24-h interval between T1 and T2. To examine the
dose response for ITI-214 effects on memory acquisition, the
drug was administered to different groups of rats via gavage in
a wide range of doses (0.1–10mg/kg). The standard paradigm is
to administer drug at 2 h prior to the T1, with effects on the d2
evaluated 24 h later during T2. ITI-214 treatment prior to T1
resulted in an increase in the rats’ ability to discriminate between
objects at T2, i.e., d2 was different from chance (d2 = zero)
performance with effective doses at 1 and 3 mg/kg (Fig. 1a).
These were intermediate effects as the d2measures for these two
doses were not different from vehicle (F(5,18) = 2.09, n.s.).
Under these conditions, ITI-214 had no effect on exploratory
behavior measured during T1 or T2 (Table 3).
The effect of ITI-214 (0.1–10 mg/kg) on memory retrieval
was evaluated by dosing the compound orally to rats 2 h prior
to the T2 exploration session. ITI-214 resulted in significant
increases in the d2 at doses ranging from 0.3 to 3 mg/kg, i.e.,
different from chance level, with a full effective dose at 1 mg/
kg. This effective dose was statistically different from vehicle
as well (F(5,119) = 4.65, p < 0.001; Fig. 1b). Given the effects
of ITI-214 on both acquisition and retrieval processes, we
examined the potential for synergistic effects of the sub-
threshold doses of the drug on memory performance. For
these studies, discriminatory behavior during T2 was mea-
sured in rats that had received a sub-threshold dose for mem-
ory acquisition (0.3 mg/kg) 2 h prior to T1 in conjunction with
a sub-threshold dose (0.1 mg/kg) for effects on memory re-
trieval 2 h prior to T2. As shown in Fig. 1c, the combined
dosing of ITI-214 at sub-effective doses prior to T1 and T2
resulted in a full increase in discrimination behavior, i.e., dif-
ferent from chance performance as well as vehicle treatment
(t(38) = 4.35, p < 0.001). Importantly, ITI-214 had no effect
on exploratory behavior in these experiments, whether tested
during T1 or T2 periods (Tables 4 and 5).
Table 3 Exploration times (in s) with administration of ITI-214 2 h before T1 in the NOR: acquisition. Different dosages of ITI-214 were administered















e1 28.26 (2.19) 28.38 (1.86) 27.55 (1.62) 27.97 (1.78) 27.28 (1.74) 26.21 (1.97)
e2 25.68 (1.50) 27.33 (1.48) 26.10 (1.69) 29.38 (1.38) 28.73 (1.62) 28.15 (1.38)
No significant differences were found between treatment conditions in exploration times in T1 (e1: F(5,119) = 0.18, n.s.) and in T2 (e2: F(5,119) = 0.94,
n.s.)
Table 4 Exploration times (in s) with administration of ITI-214 2 h before T2 in the NOR: retrieval. Different dosages of ITI-214 were administered















e1 26.48 (1.59) 29.32 (1.82) 28.83 (1.84) 26.81 (1.72) 27.20 (1.90) 30.59 (1.98)
e2 29.30 (2.19) 28.78 (2.08) 29.31 (1.52) 33.64 (2.35) 28.60 (1.13) 30.52 (1.87)
No differences were found between treatment conditions in exploration times in T1 (e1: F(5,119) = 0.81, n.s.) not in T2 (e2: F(5,119) = 0.99, n.s.)
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The effects of ITI-214 on memory consolidation were ex-
amined by dosing the drug at specified times after the T1
exploratory session. To evaluate drug effects on the early con-
solidation of memory, ITI-214 was administered orally to
groups of rats at a range of doses (1–10 mg/kg) shortly after
the completion of the T1 period. ITI-214 administration re-
sulted in an intermediate increase in d2, i.e., different from
chance level, in animals that had received a 3 mg/kg dose
within 4 min after T1 (Fig. 2, top panel). In this case, the d2
did not differ from vehicle (F(3,92) = 1.88, n.s.). Drug effects
on the late phase of memory consolidation were studied by
administering ITI-214 (0.1–3 mg/kg) 3 h after the T1 period.
Twenty-one hours later, during T2, animals that had been
treated with doses of 1 or 3 mg/kg ITI-214 displayed increases
in d2 scores compared with chance performance and signifi-
cantly different from vehicle (F(4,67) = 4.18, p < 0.01) with a
full effective dose of 1 mg/kg. The results indicate improved
late consolidation (Fig. 2, bottom panel). There were no ef-
fects on exploratory behavior in these consolidation experi-
ments (Tables 6 and 7).
We calculated the plasma concentration of ITI-214 associ-
ated with the highest dose of the drug (i.e., 3 mg/kg) having
effects on memory measured 2 h after drug administration.
The plasma level of the drug at this time was 30.1 ± 13.4 ng/
ml (N = 12 rats) which corresponds to a free plasma concen-
tration of 120 pM ITI-214. It should be noted that this free
plasma level is close to the Ki values of the compound for
inhibition of recombinant or bovine PDE1 enzymes (34–
58 pM, Table 1) and well below the Ki of the compound for
inhibition of the closest other PDE enzyme, PDE4D (33 nM,
Table 1).
Pharmacokinetic analysis of drug-drug interactions
between ITI-214 and risperidone in rats
In order to evaluate the behavioral effects of ITI-214 achieved
when dosed adjunctively with other psychiatric medications,
we examined possible drug-drug interactions between the
compound and the widely used antipsychotic medication, ris-
peridone. Brain and plasma levels of risperidone and its active
metabolite, paliperidone, were measured in samples from rats
treated orally with risperidone (2 mg/kg, po) co-administered
with vehicle solution (0.5 % CMC in water) or ITI-214 (3 mg/
kg, po) in vehicle. One hour after drug treatment, risperidone,
and the major metabolite, paliperidone, were abundant in rat
brain homogenate and in plasma. Co-treatment of animals
with ITI-214 had no significant effect on levels of risperidone
in brain (22 ± 8 ng/ml in rats receiving vehicle and 16 ± 7 ng/
ml in rats receiving ITI-214), or in plasma (85 ± 31 ng/ml in
rats receiving vehicle and 65 ± 28 ng/ml in rats receiving ITI-
214) (Table 8). Paliperidone was also detected in high levels in
the brain (15 ± 4 ng/ml) and plasma (162 ± 70 ng/ml). In sum-
mary, co-administration of ITI-214 with risperidone did not
significantly alter paliperidone levels in either rat brain (15 ±
5 ng/ml) or plasma (197 ± 91 ng/ml) (Table 8).
The effect of ITI-214 on conditioned avoidance responding
Based on pharmacokinetic data indicating a lack of drug-drug
metabolic interactions between ITI-214 and the antipsychotic
drug (Table 8), risperidone, we next evaluated possible inter-
actions between ITI-214 and risperidone on antipsychotic-like
Table 5 Exploration times (in s) with administration of suboptimal
dosages of ITI-214 2 h before T1 and T2 in the NOR: acquisition and
retrieval. Suboptimal dosages of ITI-214 were administered 2 h before T1
(0.3 mg/kg) and 2 h before T2 (0.1 mg/kg). The delay interval between
the first and second trial was 24 h. n = 20 per experimental condition
Time
PO
T1 −2 h / T2 −2 h
Vehicle / Vehicle
ITI-214
T1 −2 h / T2 −2 h
0.3 mg/kg / 0.1 mg/kg
ITI-214
e1 31.90 (1.86) 30.43 (2.16)
e2 30.80 (1.43) 28.78 (1.26)
No differences were found between treatment conditions in exploration
times in T1 (e1: t(38) = 0.52, n.s.) and T2 (e2: t(38) = 0.68, n.s.)
Fig. 2 Effect of ITI-214, given after T1, on memory consolidation as
measured in NOR. The effect of ITI-214 on different phases of memory
consolidation was measured by dosing either 4 min after T1 (early con-
solidation, top panel; n = 20 per experimental condition) or 3 h after T1
(late consolidation; bottom panel; n = 12 per experimental condition).
Discrimination index (d2) is expressed as mean ± SEM for n = 20 rats.
The d2 measures after drug treatment were significantly different from
zero (#p < 0.05; ###p < 0.001, one-sample t tests). Different from vehicle
(**p < 0.01, Bonferroni post hoc tests)
3120 Psychopharmacology (2016) 233:3113–3124
activity, as measured in the conditioned avoidance responding
(CAR) paradigm in rats. Avoidance behavior was measured in
rats after training in the CAR paradigm and tested after treat-
ment with either a sub-threshold or supra-threshold dose of the
antipsychotic medication, risperidone (0.2 or 0.8 mg/kg, i.p.),
or vehicle solution (acidified saline). As anticipated, adminis-
tration of the sub-threshold dose of risperidone (0.2 mg/kg)
had no effect on the percent avoidances, whereas the higher,
effective dose of risperidone (0.8 mg/kg) resulted in a signif-
icant inhibition of avoidance behaviors recorded (Fig. 3).
When administered orally to rats, ITI-214 (1 mg/kg in 0.5 %
CMC vehicle) alone had no significant effect on the percent
avoidances. Furthermore, the same dose of ITI-214 did not
affect avoidance behavior displayed by rats given the effective
0.8 mg/kg dose of risperidone (Fig. 3). Neither risperidone nor
ITI-214 had significant effects on the number of escape fail-
ures in the CAR paradigm.
Discussion
ITI-214 is an orally-bioavailable, small-molecule PDE1 inhib-
itor (Li et al. 2016) with picomolar affinity and high selectivity
(1000-fold) versus other PDE enzymes. The PDE1 inhibitor
displayed minimal off-target binding interactions, determined
by surveying a broad range of 70 key targets represented in a
standard panel of receptors, kinases, and enzymes linked to
side effect liabilities.
Oral administration of ITI-214 was found to improve mem-
ory performance in rats, as reflected by effects on memory
acquisition, consolidation, and retrieval. The effects of ITI-
214 on memory were observed at dose levels that did not
affect exploratory behavior or basal locomotor activity.
Furthermore, these effects were expressed across a broad
range of drug doses. The efficacy of ITI-214 in improving
memory performance is consistent with the demonstrated role
of both cAMP and cGMP signaling pathways in the circuitry
of learning and memory (Kandel 2012; Prickaerts et al. 1997;
Reneerkens et al. 2009). Several PDE enzymes have been
shown to enhance memory performance in animals, including
inhibitors of PDE5 (cGMP-specific) and PDE2 (both cAMP-
and cGMP-specific) (Reneerkens et al. 2009). Another PDE
enzyme implicated in memory is PDE4 (cAMP-specific),
which has been demonstrated to modulate memory perfor-
mance through genetic and pharmacological manipulations
(Barad et al. 1998; Bourtchouladze et al. 1998). As shown
here, ITI-214 is about 1000-fold more selective for inhibition
of PDE1, compared with PDE4D. The optimal effects of ITI-
214 on acquisition processes, shown here, were associated
with plasma levels of ITI-214 corresponding to a brain free
fraction estimated to be 120 pM ITI-214. This brain level of
compound is close to the Ki of the drug for PDE1, but far
below the Ki (38 nM) for inhibition of the closest PDE4 iso-
form, PDE4D. Although we cannot entirely discount possible
influences of PDE4 enzyme inhibition in the observed mem-
ory effects of ITI-214, these data strongly support primary
mediation of the effects through PDE1 inhibition.
The improvements in memory performance seen with ITI-
214 are likely to reflect the substrate selectivity of the PDE1
enzyme family. As described by Izquierdo et al. (2002) and
later by Rutten et al. (2007), cAMP and cGMP appear to
subserve predominant roles in different phases of memory
formation. PDE family enzymes that selectively regulate
cAMP availability, like the PDE4 inhibitor rolipram, are spe-
cifically effective at promoting late consolidation (Rutten et al.
2007; Bollen et al. 2014). In contrast, inhibitors that promote
cGMP, like the PDE5 inhibitor sildenafil, are most effective at
enhancing early consolidation processes (Rutten et al. 2007;
Table 6 Exploration times (in s) with administration of ITI-214 shortly after T1 in the NOR: early consolidation. Different dosages of ITI-214 were











e1 29.58 (2.83) 26.36 (1.93) 25.02 (2.20) 30.01 (1.62)
e2 25.56 (1.51) 29.66 (1.94) 30.55 (1.84) 31.35 (1.71)
No differences were found between treatment conditions in exploration times in T1 (e1: F(3,92) = 1.24, n.s.) and T2 (e2: F(3,92) = 2.15, n.s.)
Table 7 Exploration times (in s) with administration of ITI-214 3 h after T1 in the NOR: late consolidation. Different dosages of ITI-214 were













e1 27.02 (1.71) 26.20 (1.95) 29.36 (3.22) 25.93 (1.53) 25.62 (1.89)
e2 30.97 (1.84) 32.81 (2.24) 29.64 (2.15) 27.86 (2.43) 28.34 (2.95)
No differences between treatment conditions in exploration times in T1 (e1: F(4,67) = 0.43, n.s.) and T2 (e2: F(4,67) = 0.68, n.s.) were found
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Bollen et al. 2014). PDE2A, an enzyme that controls both
cAMP and cGMP levels, exerts effects on both acquisition
and consolidation of memories (Rutten et al. 2007; Boess et
al. 2004; Akkerman et al. 2015; Rutten et al. 2006). Taken
together, we interpret the present data, demonstrating effects
of ITI-214 across a wide dose range, as indicative of potent
regulation by PDE1 of memory performance through actions
on the acquisition, early and late consolidation, and retrieval
of information. Of note, considering the Tmax of ITI-214
(~1.5 h), the intermediate memory improvement observed
when ITI-214 is given 4 min after T1 (early consolidation
paradigm) might be explained, in part, by effects of the drug
on late consolidation processes. That is to say, a 3 mg/kg dose
of ITI-214 given immediately after T1 may deliver the dose
level (1 mg/kg) necessary for a full effective late consolidation
3 h after T1.
The potent effects of ITI-214 onmemory performance like-
ly reflect the high abundance of PDE1 isoforms in brain neu-
rons involved in learning and memory. PDE1A, 1B and 1C
isoforms are abundantly expressed in frontal cortex, hippo-
campus, and striatum (Lakics et al. 2010). Although there is
some debate about the exact roles for each brain region in the
NOR, the hippocampus is considered as the site where object
information from the perirhinal cortex is integrated with con-
textual information from the parahippocampal (or postrhinal
in rat) cortex and temporal information from the frontal cortex,
thus underlying the formation of a complete episodic memory
(e.g., Winters and Bussey 2005; Aggleton and Brown 2006;
Eichenbaum et al. 2007; Berkers et al. 2014). Though the
present data are promising, it is clear that in order to have a
view on the full potential of ITI-214 to treat cognitive deficits
in schizophrenia and other disorders, the effects of the PDE1
inhibitor need to be investigated in other domains, including
working memory per se, information processing, and atten-
tion, relevant to cognitive impairments specific for these dis-
orders (for review, see Young et al. 2009). For example,
follow-up studies to evaluate effects of ITI-214 on working
memory in paradigms such as the radial arm maze (Young et
al. 2009) or the delayed non-matching to position (DNMTP)
tasks (Dudchenko et al. 2013), and those that report on atten-
tion and speed of information processing, such as the 5-choice
serial reaction time test (Young et al. 2004), would be partic-
ularly informative. Testing of ITI-214 in paradigms for schizo-
phrenia using pharmacologically induced deficits (e.g., chron-
ic PCP or MK-801) would also be very useful (e.g., see
Rajagopal et al. 2014). Many of the aforementioned tasks
a r e r ep r e s en t ed i n t h e Camb r i dge Au toma t ed
Neuropsychological Testing Assay Battery (CANTAB) which
could be used in future studies to translate the results with ITI-
214 in rodent paradigms into non-human primate and human
patient populations (Young et al. 2009; Young and Geyer
2015).
The antipsychotic-like activity of risperidone, as measured
by blockade of conditioned avoidance responding (CAR), was
found to be equivalent in the absence or presence of an opti-
mal memory-enhancing dose of ITI-214. Co-administration of
this dose of ITI-214 with risperidone had no significant effect
on the brain and plasma level of parent drug or its major active
metabolite, paliperidone. The lack of effect of the ITI-214 on
antipsychotic-like activity of risperidone and the absence of
significant drug-drug interaction with this antipsychotic med-
ication supports its potential as an adjunctive treatment for
schizophrenia.
Table 8 Effect of co-administration to rats of ITI-214 and the antipsy-
chotic drug, risperidone, on plasma and brain concentration of risperidone
and paliperidone. Rats were given vehicle solution (0.5 % CMC in water)
or ITI-214 (3 mg/kg, po) in vehicle. All rats received a dose of risperidone
(2 mg/kg, po) prepared as an even suspension in 0.5 % CMC. One hour
later, the rats were killed and blood and brain tissue collected for quanti-
tation of levels of risperidone, and the major metabolite, paliperidone, in
brain homogenate and in plasma, using LC/MS. Levels of both com-
pounds are expressed as ng/ml ± SD (n = 3 animals/treatment condition)
Dosing condition Risperidone (2 mg/kg) Risperidone + ITI-214 (3 mg/kg)
Analyte Risperidone, ng/ml Paliperidone, ng/ml Risperidone, ng/ml Paliperidone, ng/ml
Plasma 85 ± 31 162 ± 70 65 ± 28 197 ± 91
Brain 22 ± 8 15 ± 4 16 ± 7 15 ± 5
Fig. 3 Effect of ITI-214 on performance of rats in the conditioned avoid-
ance response (CAR) paradigm. The conditioned avoidance response was
measured in rats treated with ITI-214 (1 mg/kg, po, −60 min) alone or in
combination with the antipsychotic medication, risperidone (0.2 or
0.8 mg/kg ip, −20 min). Data are shown as medians ± semi-interquartile
range based on repeated observations of the same eight animals rotated
over all treatment groups serving as their own controls in a
counterbalanced change-over design. **p < 0.001 compared with vehicle
alone (Wilcoxonmatched-pairs signed-ranks test); ns not significant com-
pared with vehicle alone
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In conclusion, cognitive impairment is widely accepted as a
core feature of schizophrenia (Tamminga et al. 1998; Hoff et al.
1999; Lieberman et al. 2005). Patients with first-episode schizo-
phrenia score one to two standard deviations below healthy
control subjects on cognitive tasks (Hoff et al. 1999). Residual
symptoms including negative symptoms, depression, and cog-
nitive impairment substantially contribute to the diminished
quality of life of patients with schizophrenia (Ueoka et al.
2011) even after the acute hallucinations and delusions are con-
trolled. Current antipsychotic medications do not effectively
improve, and often worsen cognition in patients (Cancelli et
al. 2009). The present study provides preclinical data
supporting the efficacy of a potent and selective PDE1 inhibitor,
ITI-214, for enhancement of memory performance in a manner
which does not significantly alter antipsychotic activity of a
widely used antipsychotic medication, risperidone. Recently,
ITI-214 has been found to be safe and well-tolerated in phase
I human clinical safety evaluations in healthy volunteers and
patients with schizophrenia. The potential of PDE1 inhibitors
like ITI-214 for improvement of cognitive performance in pa-
tients with neuropsychiatric and neurological indications will
require further validation as the agent undergoes comprehensive
human clinical evaluation.
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